WibiWorks Therapeutics, Inc. [WWT], a developer of breakthrough immunotherapies, has named Thomas Isett as its new Chief Executive Officer. Mr. Isett, who has been Acting CEO since February, was recently with GE Healthcare-Life Sciences, where he was General Manager, BioProcess.
WWT’s Founder and Chief Scientific Officer, Dr. Aline Betancourt, said “Having Tom join our team is the next major step in the evolution of the company. His successful track record of establishing and growing business units via innovative strategy and sound execution will be critical to our scale-up. Coupled with his deep experience in the cell therapy field, Tom is uniquely qualified to help us realize our vision to bring our novel immunotherapies to market and help those suffering from cancer and autoimmune disorders”.
Prior to GE, Isett was Head of Cell Processing Technologies at Lonza Group, a multinational biotechnology and contract manufacturing organization. Previously, he founded the Advanced Bioprocessing business unit [BU] while at Becton Dickinson & Co., [BD], and quickly led it to over $60M in revenues. He won awards for BU management while at GE and BD.
“WWT has a a highly promising technology platform”, added Isett. “Dr. Betancourt’s discoveries shed light on the lead role that mesenchymal stem cells [MSCs] play in modulating the body’s immune responses. Those insights paved the way for the development of our ability to activate MSCs in different ways to safely treat different types of disease. I’m simply thrilled to have the opportunity to work with the team to develop and commercialize cell therapies with such immense therapeutic potential”.